AstraZeneca’s Farxiga claims first SGLT2 kidney disease OK from FDAAstraZeneca is already seeing sales rocket for its SGLT2 inhibitor Farxiga in heart failure, and is expected to Share XAstraZeneca’s Farxiga claims first SGLT2 kidney disease OK from FDAhttps://pharmaphorum.com/news/astrazenecas-farxiga-gets-first-kidney-disease-ok-from-fda/
Crowded psoriasis market cuts Lilly’s mirikizumab ambitionsEli Lilly has walked away from a major indication for its blockbuster hopeful mirikizumab, shelving plans to file Share XCrowded psoriasis market cuts Lilly’s mirikizumab ambitionshttps://pharmaphorum.com/news/crowded-psoriasis-market-cuts-lillys-mirikizumab-ambitions/
Lilly’s Olumiant flunks COVID-19 trial – or does it?Eli Lilly’s JAK inhibitor Olumiant has missed its main objective in a phase 3 trial in hospitalised COVID-19 Share XLilly’s Olumiant flunks COVID-19 trial – or does it?https://pharmaphorum.com/news/lillys-olumiant-flunks-covid-19-trial-or-does-it/
Lilly and GSK/Vir antibody pairing offers resistant COVID-19 hopeTwo antibodies targeting different parts of the COVID-19 virus spike protein, from Eli Lilly and GlaxoSmithKline/Vir Biotech, can Share XLilly and GSK/Vir antibody pairing offers resistant COVID-19 hopehttps://pharmaphorum.com/news/lilly-and-gsk-vir-antibody-pairing-offers-resistant-covid-19-hope/
Regeneron’s antibody cocktail cuts COVID hospitalisation in large trialRegeneron has posted findings from a large trial of its COVID-19 antibody cocktail showing the therapy reduced risk Share XRegeneron’s antibody cocktail cuts COVID hospitalisation in large trialhttps://pharmaphorum.com/news/regenerons-antibody-cocktail-cuts-covid-hospitalisation-in-large-trial/
FDA worried about Pfizer/Lilly pain drug safety ahead of key meetingAfter a long and troubled development the fate of Pfizer/Lilly’s tanezumab painkiller injection is in the balance ahead Share XFDA worried about Pfizer/Lilly pain drug safety ahead of key meetinghttps://pharmaphorum.com/news/fda-worried-pfizer-lilly-pain-drug-safety-ahead-of-key-meeting/
Lilly’s mirikuzumab hits target in phase 3 ulcerative colitis trialA phase 3 trial of Lilly’s inflammatory diseases challenger mirikizumab in ulcerative colitis has met its target – Share XLilly’s mirikuzumab hits target in phase 3 ulcerative colitis trialhttps://pharmaphorum.com/news/lillys-mirikuzumab-hits-target-in-phase-3-ulcerative-colitis-trial/
New era of genomic medicine begins as UK approves Lilly’s RetsevmoThe UK regulator has authorised Eli Lilly’s targeted cancer drug Retsevmo for tumours with RET fusion positive lung Share XNew era of genomic medicine begins as UK approves Lilly’s Retsevmohttps://pharmaphorum.com/news/uk-authorises-lillys-ret-targeted-retsevmo/
AI platform says Olumiant could be repurposed for Alzheimer’sWith so many novel drug candidates for Alzheimer’s disease failing in clinical development, researchers in the US have Share XAI platform says Olumiant could be repurposed for Alzheimer’shttps://pharmaphorum.com/news/ai-platform-says-olumiant-could-be-repurposed-for-alzheimers/
